Opus Genetics (IRD) FCF Margin (2020 - 2026)
Opus Genetics (IRD) posted quarterly FCF Margin of 590.03% for Q1 2026, down 38422.0% year-over-year from N/an in Q1 2025, and down 131.92% quarter-over-quarter from 254.41% in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) FCF Margin (2020 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported FCF Margin for 7 consecutive years, with 590.03% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 38422.0% year-over-year to 590.03%; the TTM figure through Mar 2026 stood at 325.34% (down 11398.0% YoY), while the FY2025 annual figure was 248.33%, down 1565.0% from the prior year.
- FCF Margin eased to 590.03% in Q1 2026 per IRD's latest filing, from 254.41% in the prior quarter.
- Across five years, FCF Margin topped out at 268.95% in Q4 2023 and bottomed at 655.76% in Q2 2024.
- Historically, FCF Margin has averaged 197.67% across 5 years, with a median of 202.89% in 2025.
- Annual changes were most pronounced in 2024 — FCF Margin slumped 68267 bps — and 2025, when it soared 29944 bps.
- Opus Genetics' FCF Margin stood at 72.25% in 2022, then soared by 272 bps to 268.95% in 2023, then plunged by 164 bps to 172.9% in 2024, then slumped by 47 bps to 254.41% in 2025, then slumped by 132 bps to 590.03% in 2026.
- Business Quant data shows IRD's FCF Margin at 590.03% in Q1 2026, 254.41% in Q4 2025, and 199.97% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | -1,582.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,582.78% |
| Mar 31, 2026 | -590.03% |
| Dec 31, 2025 | -254.41% |
| Sep 30, 2025 | -199.97% |
| Jun 30, 2025 | -356.32% |
| Mar 31, 2025 | -205.81% |
| Dec 31, 2024 | -172.90% |
| Sep 30, 2024 | -132.66% |
| Jun 30, 2024 | -655.76% |
| Mar 31, 2024 | -334.07% |
| Dec 31, 2023 | 268.95% |
| Sep 30, 2023 | -25.16% |
| Jun 30, 2023 | 26.92% |
| Mar 31, 2023 | -208.46% |
| Dec 31, 2022 | 72.25% |
| Sep 30, 2021 | -732.92% |
| Jun 30, 2021 | -4,328.00% |
| Mar 31, 2020 | -63.65% |